JP Morgan 2024 – Sam Deutsch
In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica
Newsletters and Deep Dive digital magazine
In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica
There were plenty of gene therapy companies around at JP Morgan 2024, and more than a few companies focused on the microbiome.
Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.
Editor-in-chief Jonah Comstock caught up with Trevor Martin, co-founder and CEO of Mammoth Biosciences
Generative AI – large language models, or LLMs, like ChatGPT – has the potential to revolutionise almost any knowledge industry, and pharma is no exception.
Editor's Picks
Newsletters and Deep Dive
digital magazine